编号：2022-019 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □新闻发布会 \n□现场参观 \n□√其他（电话、线上会议） | □特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□路演活动 | | 参与单位名称 | | 信诚基金、泰信基金、浦银安盛基金、银河基金、建信基金、银华基金、 华夏久盈基金、申万菱信基金、华安证券、开源证券、民生证券、山西证券 | | | | | | 时间 | 2022 年 7 月 ...

编号：2022-020 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □√分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 | □新闻发布会 | □路演活动 | | 动类别 | □现场参观 | | | | □√其他（电话、线上会议） | | | | | 中国人保、中信资管、中信保诚、中信期货、 ...

编号：2022-023 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------------------------------|----------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-021 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-022 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------|-------------------|-----------------------| | 投资者关系活 \n动类别 | □现场参观 \n□√其他（电话、线上会议） | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | | | | | | 人保养老 | 中信建投基金 | 中信期货 | 民生信托 中再资产 | | | | 华夏基金 | | 长城基金 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥344,696,330.89, representing an increase of 18.36% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥47,439,961.79, up 12.69% year-on-year, while the net profit excluding non-recurring gains and losses was ¥46,140,566.11, an increase of 16.56%[5]. - The net profit for the third quarter of 2022 was CNY 104,887,601.16, an increase of 18% compared to CNY 88,933,462.49 in the same period last year[20]. - Operating income for the third quarter reached CNY 116,780,742.51, up from CNY 101,463,975.16, reflecting a growth of approximately 15.5% year-over-year[19]. - The total revenue from sales of goods and services was CNY 823,211,488.02, up from CNY 730,647,546.59, indicating a growth of approximately 12.6%[22]. Earnings Per Share - The basic earnings per share (EPS) for the period was ¥0.2863, reflecting an 8.53% increase year-on-year, while diluted EPS was ¥0.2672, up 7.14%[5]. - The basic earnings per share increased to CNY 0.6332 from CNY 0.5519, representing a growth of about 14.7%[20]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,644,701,803.91, a 7.89% increase from the end of the previous year[5]. - As of September 30, 2022, total assets were CNY 1,644,701,803.91, up from CNY 1,524,426,501.68 at the beginning of the year, indicating a growth of 7.9%[17]. - The total liabilities as of September 30, 2022, were CNY 634,030,033.19, slightly up from CNY 633,983,091.90 at the beginning of the year[17]. - The company's equity attributable to shareholders reached CNY 1,010,671,770.72, an increase from CNY 890,443,409.78, reflecting a growth of 13.5%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥62,907,793.14, showing a decrease of 35.60% compared to the previous year[10]. - The cash flow from operating activities generated a net amount of CNY 62,907,793.14, down from CNY 97,683,353.15, a decrease of about 35.5%[23]. - The company reported a cash and cash equivalents balance of CNY 89,909,959.56 at the end of the period, compared to CNY 98,284,359.97 at the end of the previous year, reflecting a decrease of approximately 4.5%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,434[12]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 34.56% of the shares, with 33,821,441 shares pledged[12]. Borrowings and Investments - The company reported a significant increase in long-term borrowings, which rose by 399.37% to ¥25,000,000.00, attributed to new borrowings during the period[10]. - The short-term borrowings decreased to CNY 257,000,000.00 from CNY 268,342,558.34, a reduction of 4.9%[17]. - The company experienced a net cash outflow from investing activities of CNY 24,225,800.33, an improvement from a net outflow of CNY 198,550,274.06 in the previous year[23]. - The financing activities resulted in a net cash outflow of CNY 21,250,130.68, compared to a net outflow of CNY 130,936,122.11 in the same period last year[23]. Operating Costs and Expenses - The total operating revenue for the third quarter of 2022 reached CNY 869,234,233.67, an increase of 16.6% compared to CNY 745,264,628.80 in the same period last year[18]. - The total operating costs for the same period amounted to CNY 749,807,302.84, reflecting a rise of 16.3% from CNY 644,773,028.12 year-on-year[18]. - The total operating expenses rose to CNY 428,144,471.00, compared to CNY 366,976,813.99, an increase of approximately 16.6%[19]. - Research and development expenses increased to CNY 12,571,577.53, compared to CNY 11,714,744.33, marking a rise of about 7.3%[19]. Government Subsidies - The company received government subsidies amounting to ¥1,724,872.07 during the reporting period, contributing to its financial performance[7].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥524,537,902.78, representing a 15.53% increase compared to ¥454,031,233.06 in the same period last year[23]. - The net profit attributable to shareholders was ¥57,447,639.37, up 22.65% from ¥46,837,320.12 in the previous year[23]. - Basic earnings per share increased by 18.48% to ¥0.3469, compared to ¥0.2928 in the previous year[23]. - The company reported a net profit excluding non-recurring gains and losses of ¥55,472,739.77, a 19.06% increase from ¥46,590,801.43 in the same period last year[23]. - The company achieved a revenue of ¥524,537,902.78, representing a year-on-year increase of 15.53% compared to ¥454,031,233.06 in the previous year[53]. - The company's main business revenue reached ¥524.1 million, representing a year-on-year increase of 15.55%[55]. - The net profit for the first half of 2022 was CNY 67,436,924.64, representing a 22.1% increase from CNY 55,092,402.91 in the previous year[168]. - The total comprehensive income for the first half of 2022 was CNY 68,806,549.84, compared to CNY 59,299,116.77 in the first half of 2021, indicating a growth of 16.4%[173]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,621,253,562.39, a 6.35% increase from ¥1,524,426,501.68 at the end of the previous year[23]. - The company's total assets reached CNY 1,614,133,879.25, compared to CNY 1,529,630,827.36 at the beginning of the year, reflecting a growth of 5.5%[164]. - The total liabilities increased to CNY 653,020,092.21, up from CNY 644,189,946.00, indicating a rise of 1.3%[165]. - The company's asset-liability ratio stands at 41.11%, a slight decrease of 0.48% from the previous year[156]. Cash Flow - The net cash flow from operating activities decreased by 26.40% to ¥43,965,639.45, down from ¥59,736,164.46 in the same period last year[23]. - The company's cash and cash equivalents increased by 489.41%, reaching ¥55,165,108.36, mainly due to reduced bank loan repayments and increased bank borrowings[53]. - The ending balance of cash and cash equivalents was ¥85,559,440.63, compared to ¥234,174,509.64 at the end of the first half of 2021, reflecting a decrease of 63.4%[178]. - The total cash outflow for operating activities was ¥504,632,815.44, which increased by 29.0% from ¥391,065,369.54 in the previous year[177]. Research and Development - The company has completed clinical phase III trials for three new traditional Chinese medicine products, including Longcen Pelvic Comfort Granules[36]. - The company has a strategic focus on expanding its market presence and enhancing its product portfolio through continuous research and development[36]. - The company's R&D investment increased to ¥13,972,036.81, up 17.51% from ¥11,889,702.71 in the previous year, reflecting a growing commitment to innovation[53]. - Research and development expenses for the first half of 2022 were CNY 12,384,704.15, a decrease of 14.7% compared to CNY 14,520,861.28 in the same period of 2021[172]. Market and Product Development - The company has a focus on gynecological and urological medications, with products like Ningpitai Capsule and Kucan Gel being unique in the domestic market[33][34]. - The leading product, Kuntai Capsule, is a national essential drug and has ranked 2nd in the gynecology medication field in the 2020 and 2021 Clinical Value Chinese Medicine Brand List[32]. - The company has established a stable supply chain for raw materials, leveraging the rich medicinal resources available in Guizhou province, which accounts for 89.81% of the 363 key varieties surveyed nationwide[51]. - The company is focused on expanding its market reach, with its products covering over 11,500 hospitals and 85,000 retail outlets nationwide[50]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, ensuring compliance with environmental regulations[95]. - The company emphasizes social responsibility by protecting investor rights, enhancing employee welfare, and engaging in community service[104]. - The company has introduced advanced energy-saving and environmental protection equipment to improve fuel utilization and reduce carbon emissions[103]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. Shareholder and Equity Information - The total number of shares before the change was 164,048,027, with a total after the change of 165,721,702, reflecting an increase of 1,673,675 shares[132]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 36.55% of the shares, totaling 60,576,547 shares, with 33,821,441 shares pledged[135]. - The company has not disclosed any significant impacts on financial metrics such as basic and diluted earnings per share due to the share changes[134]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[139].

Group 1: Event Details - The event is the "2021 Annual Performance Presentation and Investor Reception Day" scheduled for May 13, 2022, from 09:30 to 11:30 [1] - The event is organized by the Guizhou Securities Regulatory Bureau, Guizhou Securities Association, and Shenzhen Panorama Network Co., Ltd. [1] - The event will be held on the "Panorama Roadshow" platform [1] Group 2: Company Participation - Representatives from the company include Chairman and General Manager Dong Dalun, Director and Deputy General Manager Wang Jinhua, Secretary of the Board and Deputy General Manager Wang Guangping, and Chief Financial Officer Zeng Zhihui [1] - The company aims to enhance communication with investors and improve investor relations management [1] Group 3: Investor Engagement - The company is collecting questions from investors in advance to address common concerns during the event [1] - Investors can submit their questions via a dedicated webpage [1] - The company encourages active participation from investors [1]

贵阳新天药业股份有限公司 2022 年第一季度报告全文 | 证券代码：002873 | 证券简称：新天药业 | 公告编号：2022-035 | | --- | --- | --- | | 债券代码：128091 | 债券简称：新天转债 | | 贵阳新天药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 249,216,213.05 | 214,656,599.9 ...

Financial Performance - The company's operating revenue for 2021 was ¥969,844,472.18, representing a 29.15% increase compared to ¥750,946,390.31 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥100,605,308.02, a 35.76% increase from ¥74,103,210.31 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥93,839,366.09, up 32.21% from ¥70,977,065.18 in 2020[20]. - The basic earnings per share for 2021 was ¥0.6193, a 34.48% increase from ¥0.4605 in 2020[20]. - The total operating revenue for 2021 was ¥969,844,472.18, representing a year-on-year increase of 29.15% compared to ¥750,946,390.31 in 2020[59]. - The main business revenue accounted for ¥968,695,455.00, which is 99.88% of total revenue, with a year-on-year growth of 29.13%[62]. - The gynecological product category generated ¥686,491,923.90, making up 70.78% of total revenue, with a growth rate of 31.83%[59]. - The gross profit margin for the main business was 79.28%, slightly up by 1.27% from the previous year[62]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[132]. - The company plans to set a revenue guidance of 1.5 billion RMB for the next fiscal year, projecting a growth rate of 25%[132]. Cash Flow and Investments - The net cash flow from operating activities decreased by 29.28% to ¥124,300,304.12 from ¥175,767,527.16 in 2020[20]. - The total cash inflow from operating activities increased by 19.92% to ¥1,002,079,539.69 in 2021 compared to ¥835,614,919.37 in 2020[73]. - Investment cash inflow surged by 93.15% to ¥553,082,000.00 in 2021, up from ¥286,351,416.78 in 2020[74]. - Financing cash inflow dropped by 47.07% to ¥300,811,607.40 in 2021, compared to ¥568,300,000.00 in 2020[74]. - The total amount of capitalized R&D investment decreased by 43.76% to ¥8,512,930.57 in 2021 from ¥15,135,456.00 in 2020[71]. - The company has allocated RMB 8,000 million to purchase wealth management products and RMB 3,000 million to temporarily supplement working capital[88]. - The company reported a usage rate of 34.83% for the raised funds, indicating that a significant portion remains unutilized[87]. - The company has committed to using the remaining funds from terminated projects for new initiatives, specifically the traditional Chinese medicine formula granule project[92]. Research and Development - The company has established three major R&D bases in Shanghai and Guiyang, forming a systematic R&D structure[45]. - The company has developed three new traditional Chinese medicine products that have completed Phase III clinical trials, with a total of 445 provincial standard varieties of traditional Chinese medicine formula granules and 60 national standard filings[52]. - Research and development expenses increased by 53.26% to ¥20,376,605.27, reflecting a focus on enhancing product offerings[69]. - The company emphasizes a "production generation, reserve generation, development generation" approach in its R&D strategy for traditional Chinese medicine[43]. - The company is committed to enhancing its research and development efforts to drive innovation in its product offerings[122]. Market and Product Development - The company has achieved a market scale of over 100 million for multiple key products, including Kuntai Capsule and Kushi Gel[35]. - The company plans to enhance market promotion for its exclusive products, aiming to expand market share and attract innovative talent[36]. - The company aims to strengthen the promotion of existing major products and enhance sales team construction, with a focus on expanding the OTC market and increasing online sales investment[102]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[132]. - The company plans to produce new products such as Re-Lin-Qing Syrup and Xie-Yu-Jiang-Zhi Capsule in the future[46]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations[111]. - The board of directors consists of three independent directors, meeting the requirement of one-third of the total board members[112]. - The company has a dedicated internal audit department to oversee daily operations and major related transactions[114]. - The company has established a clear organizational structure to prevent fraud risks through separation of incompatible duties[162]. - The company has made provisions for bad debts based on prudence principles at the end of the reporting period[105]. Environmental Responsibility - The company has maintained compliance with environmental regulations, but future changes in laws may increase environmental costs[106]. - The company has implemented advanced environmental management technologies to reduce carbon emissions, improving fuel utilization efficiency and reducing CO2 emissions[179]. - The company has established a management system for energy efficiency and carbon emission reduction[179]. - The company has a solid waste management system in place, including the collection and recycling of waste packaging materials and the disposal of hazardous waste by qualified units[176]. - The company conducts annual emergency response training and drills as part of its environmental incident emergency plan[177]. Employee and Stakeholder Relations - The company has a total of 261 production personnel, 382 sales personnel, and 175 technical personnel[151]. - The company has established a salary system based on employee contributions, with performance-based compensation for market personnel[152]. - Employee rights are protected through a competitive compensation system and a focus on employee health and corporate culture[181]. - The company has implemented a stock incentive plan for its executives, which is expected to align their interests with those of shareholders[122]. - The management team emphasizes a commitment to sustainability, with plans to implement eco-friendly practices in production by 2023[132]. Risk Management - The company acknowledges the risks associated with drug development, including long cycles and high costs, and is committed to improving R&D efficiency and protecting intellectual property[104]. - The company has implemented measures to control accounts receivable risk, including enhancing the assessment of the business operation center and monitoring the entire sales process[105]. - The company has established a risk response strategy based on its strategic goals and development needs[162]. - The company has actively engaged with stakeholders to balance interests and promote sustainable development[115]. - The company has made improvements to its internal control system to adapt to changing external environments and internal management requirements[162].